| Literature DB >> 33191824 |
Max Berrill1, Jola Karaj1, Georgiana Zamfir2, Jordan Colman2, Rachel Mason1, Saeed Akbar1, Shashank Sharma1, Frances Sheehan2, Kanchan Dhamija3, Felicity Saltissi2, Aigul Baltabaeva4, Sujoy Saikia1.
Abstract
Objectives: Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) has caused enormous strain on health-care systems worldwide. Early recognition of prognostic markers and appropriate management of patients with coronavirus disease 2019 (Covid-19) remains a major global health concern, particularly when resources are limited. We undertook a study to see if basic tests can inform frontline clinicians of disease trajectory in individual patients with COVID-19.Entities:
Keywords: CXR; Covid-19; United Kingdom; radiograph: coronavirus
Mesh:
Year: 2020 PMID: 33191824 PMCID: PMC7754924 DOI: 10.1080/17476348.2021.1850278
Source DB: PubMed Journal: Expert Rev Respir Med ISSN: 1747-6348 Impact factor: 3.772
Demographics
| Full cohort | Alive at 30 d ( | Dead at 30 d ( | ||
|---|---|---|---|---|
| Gender (male – %) | 44.0 | 48.5 | 35.3 | |
| Age (y), mean ± SD, range | 65.2 ± 19.6 (15–94) | 60.2 ± 21.2 (15–94) | 75.0 ± 10.9 (55–94) | |
| Height (m), mean ± SD | 1.71 ± 0.11 | 1.72 ± 0.11 | 1.70 ± 0.12 | |
| Weight (kg), mean ± SD | 82.0 ± 20.0 | 85.3 ± 20.9 | 75.9 ± 17.3 | |
| Body Mass Index (kg/m2), mean ± SD | 27.7 ± 5.4 | 28.5 ± 5.7 | 26.3 ± 4.7 | |
| Ethnicity (n,%) | ||||
| White British | 33 (66.0%) | 23 (20.5%) | 10 (62.5%) | |
| White Other | 1 (2.0%) | 0 (0%) | 1 (6.3%) | |
| Other | 6 (12.0%) | 3 (10.7%) | 3 (18.8%) | |
| Pakistani | 2 (4.0%) | 2 (7.1%) | 0 (0%) | |
| Indian | 1 (2.0%) | 0 (0%) | 1 (6.3%) |
Comorbidities
| Full cohort | Alive at 30 d ( | Dead at 30 d ( | |
|---|---|---|---|
| Diabetes (%) ( | 17/47(36.2%) | 9/31 (29.0%) | 8/16 (50.0%) |
| Hypertension (%) ( | 27/48 (56.3%) | 15/31 (48.4%) | 12/17 (70.6%) |
| Ischemic Heart disease (%) ( | 7/48 (14.6%) | 3/31 (9.7%) | 4/17 (23.5%) |
| Heart failure (%) ( | 6/48 (12.5%) | 2/31 (6.5%) | 4/17 (23.5%) |
| Active malignancy (%) ( | 4/48 (8.3%) | 1/31 (3.2%) | 3/17 (17.6%) |
| Atrial fibrillation (%) ( | 7/48 (14.6%) | 4/31 (12.9%) | 3/17 (17.6%) |
| Chronic kidney (%) ( | 5/48 (10.4%) | 3/31 (9.7%) | 2/17 (11.8%) |
| Respiratory disease (%) ( | 17/48 (35.4%) | 12/31(38.7%) | 5/17 (29.4%) |
Presenting complaints
| Full cohort | Alive at 30 d ( | Dead at 30 d ( | |
|---|---|---|---|
| Cough (%) ( | 20/37 (54.1%) | 15/25 (60.0%) | 5/12 (41.7%) |
| Dyspnea (%) ( | 20/37 (54.1%) | 13/25 (52.0%) | 7/12 (58.3%) |
| Fever (%) ( | 18/37 (48.6%) | 14/25 (56.0%) | 4/12 (33.3%) |
| Chest pain (%) ( | 15/37 (40.5%) | 10/25 (40.0%) | 5/12 (41.7%) |
| Nausea/Vomiting (%) ( | 4/37 (10.8%) | 3/25 (12.0%) | 1/12 (8.3%) |
| Abdominal pain (%) ( | 2/37 (5.4%) | 2/25 (8.0%) | 0/12 (0%) |
Radiological features
| Full cohort | Alive at 30 d ( | Dead at 30 d ( | ||
|---|---|---|---|---|
| Normal chest x-ray ( | 3/46 (6.5%) | 3/31 (9.7%) | 0/15 (0%) | 0.541 |
| Consolidation ( | 3/46 (6.5%) | 3/31 (9.7%) | 0/15 (0%) | 0.541 |
| Airspace shadow ( | 37/46 (80.4%) | 24/31 (52.2%) | 13/15 (86.7%) | 0.696 |
| Right side airspace shadow ( | 29/46 (63.0%) | 17/31 (54.8%) | 12/15 (80.0%) | 0.117 |
| Left side airspace shadow ( | 31/46 (67.4%) | 19/31 (61.3%) | 12/15 (80.0%) | 0.317 |
| Upper Zone airspace shadow ( | 1/46 (2.2%) | 0/31 (0%) | 1/15 (6.7%) | 0.326 |
| Mid Zone airspace shadow ( | 22/46 (47.8%) | 11/31 (35.5%) | 11/15 (73.3%) | 0.027 |
| Lower Zone airspace shadow ( | 34/46 (73.4%) | 22/31 (71.0%) | 12/15 (80.0%) | 0.723 |
| Pleural effusion ( | 4/46 (8.7%) | 2/31 (6.5%) | 2/15 (13.3%) | 0.587 |
| R pleural effusion ( | 2/46 (4.3%) | 1/31 (3.2%) | 1/15 (0.67%) | 1.00 |
| L pleural effusion ( | 2/46 (4.3%) | 1/31 (3.2%) | 1/15 (0.67%) | 1.00 |
| Wong score ( | 2 (0–6) | 1.5 (0–4) | 3.0 (0–6) | 0.007 |
Laboratory variables at presentation
| All ( | Survivors ( | Non-survivors ( | ||
|---|---|---|---|---|
| White cell count ( | 7.5 ± 4.9 | 6.9 ± 5.66 | 7.9 ± 3.38 | 0.508 |
| Neutrophils ( | 5.8 ± 4.46 | 5.8 ± 4.934 | 6.3 ± 3.52 | 0.575 |
| Lymphocytes ( | 0.9 ± 0.71 | 1 ± 0.78 | 0.8 ± 0.54 | 0.14 |
| Neutrophil:Lymphocyte ( | 6.9 ± 8.8 | 6.1 ± 5.1 | 8.5 ± 12.7 | 0.305 |
| C-reactive Protein ( | 67.5 ± 102.7 | 79.0 ± 79.41 | 54.0 ± 113.5 | 0.542 |
| Albumin ( | 41 ± 7.3 | 42 ± 3.5 | 39 ± 5.8 | 0.028 |